Annovis Bio Unveils Groundbreaking Pharmacokinetic Insights for Crystalline Buntanetap in Peer-Reviewed Study

In a significant stride forward in the battle against devastating neurodegenerative diseases, Annovis Bio Inc. (NYSE: ANVS), a clinical-stage pharmaceutical company, has announced the peer-reviewed publication of crucial pharmacokinetic (PK) data for its lead drug candidate, Buntanetap (ANVS401).

The prestigious Journal of Pharmacology and Experimental Therapeutics (JPET) has published findings that illuminate the superior properties of a novel crystalline form of Buntanetap, offering renewed hope for patients suffering from Alzheimer's and Parkinson's diseases.

The newly published research meticulously details the enhanced solubility and bioavailability of this optimized crystalline Buntanetap.

These characteristics are paramount for an orally administered drug, as they directly impact how effectively the compound can reach its therapeutic targets, especially within the complex environment of the brain. Improved bioavailability means more of the active drug can enter circulation and cross the blood-brain barrier, potentially leading to more potent and consistent therapeutic effects with lower doses.

Buntanetap is an orally administered small molecule that operates through an innovative mechanism: it inhibits the translation of multiple neurotoxic proteins, including Amyloid Precursor Protein (APP), Tau, alpha-synuclein (aSyn), TDP43, and FUS.

These proteins are widely recognized as key contributors to the pathology of various neurodegenerative conditions. By targeting these toxic proteins upstream, Buntanetap aims to prevent their accumulation and the subsequent neuronal damage that characterizes diseases like Alzheimer's and Parkinson's.

The study, co-authored by Annovis Bio’s CEO, Dr.

Maria Maccecchini, along with Dr. Jeffrey C. Chen and Dr. Kwasi Mireku, reinforces the scientific rigor and potential of Buntanetap. Dr. Maccecchini emphasized the critical importance of peer-reviewed publications, stating, “The publication of the improved pharmacokinetic characteristics of our novel crystal form of Buntanetap in JPET underscores the scientific validation and potential of our lead drug candidate.

This crystalline form demonstrates superior solubility and bioavailability, which are crucial for effective drug delivery and ultimately, for therapeutic efficacy in neurodegenerative diseases.”

This publication arrives at a pivotal time as Annovis Bio continues to advance Buntanetap through clinical trials, including a Phase 3 study for Alzheimer's disease and a Phase 2/3 study for Parkinson's disease.

The enhanced pharmacokinetic profile provides a stronger foundation for these ongoing trials, suggesting that the optimized drug form could lead to more predictable and beneficial patient outcomes. This scientific validation marks a significant milestone, reinforcing confidence in Buntanetap's potential to become a leading therapeutic option for these challenging conditions.

The detailed insights provided by this JPET publication not only validate Annovis Bio's scientific approach but also pave the way for a deeper understanding of Buntanetap's clinical promise.

The future appears brighter for patients and families grappling with neurodegenerative diseases, as Annovis Bio continues its diligent pursuit of groundbreaking treatments.